 |  |
 |
|
|
In this section we placed new antibodies for melanoma research. For your convinience, please find for each antibody at least one fresch reference of this marker use for differential diagnostic or prognostic studies of melanoma tumors.
All essential information about antibody is provided here. In case you need a detailed data sheet, please wite to us. These antibodies are still in testing for reactivity on formalin/fixed tissue sections. If you need information, please inquire.
For ordering please send your P.O. to us by fax or e-mail. |
|
| ABCB5 (ATP-binding cassette, sub-family B, member 5N:P-glycoprotein ABCB5) |
•Tumor stem or initiating cells have been proposed to exist for melanoma. Recently, Schatton et al. provided solid evidence that the doxorubicin-resistant ATP-binding cassette transporter ABCB5 marks primitive cells capable of recapitulating melanomas >>to read>>
•The self-renewal signaling pathways as well as specific markers like as CD133, ABCB5 and ABCG2 recently identified in putative melanoma cancer stem cells >>to read>>
•ABCB5+ tumour cells detected in human melanoma patients show a primitive molecular phenotype and correlate with clinical melanoma progression >>to read>> |
| f |
#16011 |
ABCB5 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| CDKN2A (isoform 1) / p16INK4a (cyclin-dependent kinase inhibitor 2A) |
•p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors >>to read>>
Other names: CDK4I; CDKN2; CMM2; INK4; INK4a; CDK4 inhibitor p16-INK4) |
| f |
#16271 |
CDKN2A |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| Flotillin 2 / FLOT2 (reggie-1; ESA1; M17S1) |
•Up-regulation of Flotillin-2 is associated with melanoma progression >>to read>>
•High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma >>to read>> |
| f |
#16538 |
Flotillin 2 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| LIVIN/BRIC7/MIL-IAP (baculoviral IAP repeat-containing 7) |
•Melanoma inhibitor of apoptosis (ML-IAP) is a potent inhibitor of apoptosis, which is highly expressed in melanomas and likely contributes to their resistance to chemotherapeutic treatments >>to read>>
•Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus >>to read>>
• ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas >>to read>> |
| f |
#16831 |
LIVIN |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| MADER / NAB2 (NGFI-A binding protein 2 ; EGR1 binding protein 2) |
| • NAB2/Mader protein may be associated with the malignant transformation of melanocytes >>to read>> |
| b |
#10000 |
Mader (NAb2) |
Price* |
| Mouse mAb |
IgG1 |
Clone: 1C4 |
widely applicable antibody for research of melanoma and other cell biology research |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-F, WB-R/NR |
229.- |
229.- |
| MCAM (melanoma cell adhesion molecule; CD146; MUC18; Muc18; Mel-CAM) |
| • A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction >>to read>> |
| b |
#10006 |
MCAM (Muc18) |
Price* |
| Mouse mAb |
IgG1 |
Clone: BA3 |
widely applicable antibody for research of melanoma and other cell biology research |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-F, WB-NR, IP-NR, FC |
229.- |
229.- |
| b |
#10005 |
MCAM (Muc18) |
Price* |
| Mouse mAb |
IgG1 |
Clone: BA4 |
widely applicable antibody for research of melanoma and other cell biology research. |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-F, WB-NR, IP-NR, FC |
229.- |
229.- |
| MDA5/IFIH1 (melanoma differentiation associated protein-5; MDA-5; Hlcd; MGC133047; IDDM19) |
| •Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis >>to read>> |
| f |
#16873 |
MDA5 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide epitope, sucessfully tested in IHC on paraffin sections |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-P, WB-R; IHC-F |
229.- |
229.- |
| MDA9 (melanoma differentiation associated protein-9; SDCBP; syndecan binding protein (syntenin); ST1; SYCL; TACIP18) |
• mda-9/Syntenin: a positive regulator of melanoma metastasis >>to read>>
• mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB >>to read>> |
| f |
#17473 |
MDA9 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| NEDD9 (neural precursor cell expressed, developmentally down-regulated 9; CAS-L; CASL; HEF1) |
| •A series of functional, biochemical, and clinical studies established NEDD9 as a bona fide melanoma metastasis gene >>to read>> |
| f |
#16950 |
NEDD9 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet. |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F, |
229.- |
229.- |
| NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog ; N-ras ; NRAS1) |
•Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro >>to read>>
•Differential oncogenic potential of activated RAS isoforms in melanocytes >>to read>>
•Improving melanoma classification by integrating genetic and morphologic features >>to read>> |
| f |
#16998 |
NRAS |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| SPP1/Osteopontin (secreted phosphoprotein 1; bone sialoprotein I, early T-lymphocyte activation 1; HGNC:11255; BNSP; BSPI; ETA-1) |
| •SPP1 and PRAME proved valuable as melanoma-specific markers capable of differentiating melanoma cells from benign naevi in the sentinel lymph nodes >>to read>> |
| f |
#17035 |
SPP1 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| PAI1 / SERPINE1 (plasminogen activator inhibitor, type I; PAI-1; PLANH1) |
| •Plasminogen activator inhibitor type 1 Is a possible indicator of increased risk for metastatic melanoma >>to read>> |
| f |
#17048 |
PAI1 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| PAR-1 (MAP/microtubule affinity-regulating kinase 2;MARK2; EMK1) |
•PAR-1 expression is the best antibody marker of recurrence risk from those >>to read>>
•Observed a significantly higher percentage of PAR-1-positive cells in the metastatic melanoma compared to dysplastic nevi (P=0.0072) and primary melanoma (P=0.0138)>>to read>>
• Overexpression of PAR-1 in atypical nevi and melanomas supports a role for PAR-1 in the initial phases of melanoma development as well as in tumor progression and metastasis >>to read>> |
| f |
#16865 |
PAR-1 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F, |
229.- |
229.- |
| PAX3 (paired box gene 3 (Waardenburg syndrome 1); WS1; CDHS; HUP2; paired domain gene 3) |
• The role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and diseas [a Review] >>to read>>
• TGF-beta targets PAX3 to control melanocyte differentiation >>to read>> |
| f |
#17065 |
PAX3 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide epitope, sucessfully tested in IHC on paraffin sections |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-P, WB-R; IHC-F, |
229.- |
229.- |
| PHLDA1/ TDAG51 (pleckstrin homology-like domain, family A, member 1; PHRIP) |
| • PHLDA1 is constitutively expressed by melanocytic nevi where it may contribute to their benign phenotype >>to read>> |
|
#10012 |
PHLDA 1 |
Price* |
| Mouse mAb |
IgG2a |
Clone: RN6E2 |
Unique antibody to Rat Ep-CAM useful in research of epithelial cells. |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-F, WB |
229.- |
229.- |
| Pmel 17/ Silver homologue (Melanocyte protein mel 17; SILV ; D12S53E; ME20; SI; SIL; gp100 ) |
| • Nuclear to non-nuclear Pmel17/gp100 expression as a discriminator between benign and malignant melanocytic lesions >>to read>> |
| f |
#17363 |
Pmel 17 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| Ribosomal protein L8 (ATP-binding cassette, sub-family B, member 5N:P-glycoprotein ABCB5) |
| • may represent a relevant vaccine target for patients with melanoma >>to read>> |
| f |
#17274 |
Ribosomal protein L8 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
| UBC9 (ubiquitin-conjugating enzyme E2I; UBE2I; (C358B7.1; P18; SUMO-1-protein ligase; ubiquitin conjugating enzyme 9; ubiquitin-conjugating enzyme E2I; ubiquitin-conjugating enzyme E2I; ubiquitin-conjugating enzyme UbcE2) |
| • evidence that the ubiquitin-conjugating enzyme, Ubc9, is expressed at high levels in melanoma-positive lymph nodes, and that it plays a crucial role in preventing advanced-stage melanomas from undergoing chemotherapy-induced apoptosis >>to read>> |
| f |
#17583 |
UBC9 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide epitope, sucessfully tested in IHC on paraffin sections. |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: IHC-P; WB-R; IHC-F |
229.- |
229.- |
| Wilms tumor 1 / WT1 (GUD; WAGR; WIT-2; WT33) |
| • Wilms tumor 1 is expressed in most melanomas but is nearly absent in nevi. Immunohistochemical analysis for Wilms tumor 1 may be clinically useful in distinguishing nevi from melanoma >>to read>> |
| f |
#17637 |
WT1 |
Price* |
| Goat pAb |
Affinity
purified |
Prepared against peptide, likely to work on formalin-fixed/paraffin embedded sections, but not tested yet |
EUR |
USD |
| Freeze-Dried |
100 mcg |
Tested Methods: WB-R; IHC-F |
229.- |
229.- |
|
|
|